New drug duo aims to stop deadly lymphoma in its tracks after transplant
NCT ID NCT07389616
First seen Feb 05, 2026 · Last updated May 15, 2026 · Updated 12 times
Summary
This study tests whether two drugs, cidabenamine and azacitidine, can keep high-risk peripheral T-cell lymphoma from returning after a stem cell transplant. About 40 adults aged 18 to 70 will receive this maintenance therapy. The goal is to see if the combination improves survival and prevents relapse.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PERIPHERAL T-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai General hospital,Shanghai Jiao Tong University School of Medicine
RECRUITINGShanghai, Shanghai Municipality, 200080, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.